Brendan Frey

How Deep Learning is Transforming Drug Discovery

Brendan Frey, CEO and Founder of Deep Genomics, will explain how AI did most of the heavy lifting in obtaining the company's first therapeutic candidate. This included discovering novel biology, designing novel compounds, prioritizing compounds by predicted potency and toxicity, creating animal models, designing animal studies and designing the clinical trial. Their AI technology is enabling Deep Genomics to explore an expanding universe of genetic therapies, and to advance novel drug candidates more rapidly and with a higher rate of success than was previously possible.

Buttontwitter Buttonlinkedin
This website uses cookies to ensure you get the best experience. Learn more